Miebo: How a European $20 Eye Drop Became an $800 Prescription in the U.S.

Classic corporate greed. Manipulating laws to rip off people. Health should be a right, not a money grab.

[View original comment]

Miebo: How a European $20 Eye Drop Became an $800 Prescription in the U.S.

Capitalism milking tears for gold.

[View original comment]

Pharma assembles an extensive ensemble cast including Rajit Kapur, Binu Pappu, Narain, Shruti Ramachandran. https://english.mathrubhumi.com/movies-music/news/malayalam-web-series-pharma-starring-nivin-pauly-to-start-streaming-on-this-date-know-when-and-where-to-watch-jpjdlgb8?utm_source=dlvr.it&utm_medium=mastodon #NivinPauly #Pharma #JioHotstar #ShrutiRamachandran #Muthumani

Top 10 DN Dược, Thiết bị y tế, Chăm sóc sức khỏe và Bệnh viện tư nhân uy tín 2025 đã được Vietnam Report công bố ngày 5/12/2025. Danh sách ghi nhận những doanh nghiệp và bệnh viện tư nhân dẫn đầu về chất lượng, độ tin cậy và đóng góp tích cực cho hệ thống y tế nước nhà. Đây là kết quả đánh giá dựa trên năng lực tài chính, uy tín truyền thông và khảo sát chuyên gia.

#Top10 #Dược #Thiếtbịyte #Chămsócsứckhoe #Bệnhviệntư #Uytín2025 #Healthcare #MedicalDevices #Pharma #Hospital #VietnamReport #Yte #

AdvantaPure achieves early USP 665 compliance, setting new standards in pharmaceutical product safety and single-use system development across multiple material lines #Pharma #Innovation

pas Spiraea qui est paraphylétique🫣. Ca veut dire quoi ? J'explique ici : Entre polyphonie polyphyle et paraphilie paraphyle, www.monvoisin.xyz/entre-polyph... Merci @especes.bsky.social@bsky.brid.gy n°36, juin 2020 #botanique #pharma @ssaft.com@bsky.brid.gy

Entre polyphonie polyphyle et ...

Je n'avais pas tilté que l'aspirine était une marque déposée ! Par Bayer, en 1899. Pourquoi a-spirine ? A de acétylsalicylique, et SPIR de Spiraea ulmaria, ancien nom de la Reine-des-prés, dont le nouveau nom est Filipendula ulmaria, "fils qui pendouillent", parce que Filipendula est un vrai clade, pas Spiraea, qui est paraphylétique🫣. Ca veut dire quoi ? J'explique ici : Entre polyphonie polyphyle et paraphilie paraphyle, https://www.monvoisin.xyz/entre-polyphonie-polyphyle-et-paraphilie-paraphyle-especes-n36-juin-2020/
Merci Espèces n°36, juin 2020
#botanique #pharma

Bộ Y tế công bố danh sách 46 doanh nghiệp ngoại từ 12 quốc gia có thuốc nhập khẩu vi phạm chất lượng, phải tiền kiểm 100% mọi lô thuốc! Cục Quản lý Dược đảm bảo an toàn người dùng. #SứcKhỏe #Y tế #Thuốc #Vi phạm #Health #Medicine #Pharma #Vietnam

https://vietnamnet.vn/bo-y-te-cong-bo-46-doanh-nghiep-ngoai-co-thuoc-nhap-khau-vi-pham-2468813.html

CTT Pharma advancing micelle thin-film drug delivery tech, preparing SEC reporting, expanding manufacturing capabilities, and pursuing innovative oral strip technologies in 2026 #Pharma #Innovation

How do you connect pharma professionals, master’s students, and R users in one local community?

Find out how Ronak Shah and the Pune R User Group are doing exactly that with campus-based and hybrid meetups supporting India’s fast-growing pharma + R ecosystem.

New R Consortium interview: https://r-consortium.org/posts/connecting-pharma-students-and-r-ronak-shah-on-strengthening-pune-r-ecosystem/

#rstats #opensource #pharma #datascience #rcommunity #Pune #India

Trump admin claims win as UK bows to pressure on NHS drug spending – POLITICO

The NICE threshold will rise to £25,000 to £35,000 for every quality adjusted life year. In return for…
#NewsBeep #News #Headlines #Benchmarks #department #DonaldTrump #Dumping/Duties #environment #imports #industry #Negotiations #patients #Pharma #Research #tariffs #UK #UnitedKingdom
https://www.newsbeep.com/283825/

NanoViricides partners with Only Orphans Cote to advance NV-387 orphan drug strategy, targeting breakthrough treatments for Smallpox, MPox, and Measles #Pharma #Innovation

Pharma Screener Wrap-Up 🧬

#Pharma delivered scattered results across every metric, no uniform pattern anywhere.

That reflects an industry under constant pressure: patents, pricing, pipelines, and regulation.

Time to pick who moves to ‘Validation’!

🧵 (1/5)

#TheBarnBlog #FindItFinancials #valueinvesting #finance #markets

For many of us with rare diseases, there's no cure or treatments for easing our ailments as there's not enough incentive for the Big Pharma to invest in R&D to cure diseases which doesn't affect many.

Occasionally, some medicines do come to market for treating a rare disease but with astronomical prices. I personally know people whose medicine costs almost as much as a small house in India for a single dose/month (usually they require the medicine life long).

contd.

#raredisease #pharma

Eli Lilly is the first health-care company to hit $1T market value, thanks to its weight-loss drugs. The question now: Is this successful innovation, or proof the US drug pricing system is fundamentally broken for patients?

https://tinyurl.com/3t5fds6h

#EliLilly #Pharma #DrugPricing #Healthcare

"A new wave of Chinese low-cost innovation will therefore wash around the world. It will do so in different ways. China’s cheap medicines could bring benefits, and particularly to the developing world. But for its companies America’s lucrative market, which is the source of 70% of global pharma profits, is the juiciest prize. And China’s importance for the pipelines of Western drugmakers means that the relationship could even be symbiotic. Robotaxis, by contrast, are likely to follow the more usual path for China’s tech exports. They are blocked by America, which has its own industry and acute security concerns, but will probably gain a foothold in other places, where domestic efforts at autonomy lag far behind.

How should the rest of the world respond? The competition risks hollowing out Western economies. Where there is evidence of Chinese dumping and subsidies, counter-measures against Chinese exports are justified and necessary. Where there are security risks action is justified, too. The data collected by robotaxis could pose a surveillance threat; Chinese pharma has suffered corruption scandals. Yet knee-jerk protectionism in the name of security or safety would be a mistake. Blocking or limiting the fruits of Chinese innovation would deprive consumers of the benefits of cheaper and better drugs and transport at a time when voters worry about affordability.

That is why it would be better for Western economies to rethink how innovation works at home."

https://www.economist.com/leaders/2025/11/27/what-china-will-dominate-next

#China #Innovation #RoboTaxis #Pharma

𝗔𝘀𝗶𝗮’𝘀 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗿𝘂𝗴𝘀 𝗺𝗮𝗿𝗸𝗲𝘁 𝗴𝗿𝗼𝘄𝘀 𝘀𝘁𝗲𝗮𝗱𝗶𝗹𝘆

Targeted therapies, immuno-oncology & rising cancer prevalence boost demand.
𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://www.kenresearch.com/industry-reports/asia-oncology-drugs-market-research-report?utm_source=X&utm_medium=Referral&utm_campaign=Aniket
#Asia #Oncology #Pharma